BGLC
BioNexus Gene Lab Corp.
There isn't enough reported data to score BGLC yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BGLC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
BGLC's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BGLC PE Valuation
BGLC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BGLC Forward outlook
There aren't enough analyst estimates for BGLC to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BGLC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2022 | -$0.07 | -105% |
| Q2 2022 | -$0.02 | -101% |
| Q1 2022 | $0.07 | -95% |
| Q4 2021 | $0.06 | -96% |
| Q3 2021 | $1.44 | +586% |
| Q2 2021 | $1.44 | +586% |
| Q1 2021 | $1.44 | +1340% |
| Q4 2020 | $1.44 | +$1.44 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 1,943% for BGLC versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
BGLC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $76.2K | -97% |
| Q1 2026 | $22.8K | -99% |
| Q4 2025 | $483.8K | -81% |
| Q3 2025 | $2.5M | -3.3% |
| Q2 2025 | $2.3M | +14% |
| Q1 2025 | $2.1M | -10% |
| Q4 2024 | $2.5M | +11% |
| Q3 2024 | $2.6M | +3% |
BGLC's revenue has slid since its 2020 peak: $76,156 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -371% | -344 points |
| Q1 2026 | -2366% | -2337 points |
| Q4 2025 | -214% | -197 points |
| Q3 2025 | -28% | +23 points |
| Q2 2025 | -27% | -40 points |
| Q1 2025 | -29% | -26 points |
| Q4 2024 | -16% | -28 points |
| Q3 2024 | -51% | +48 points |
BGLC's operating margin was −371% last quarter, down 344 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BGLC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BGLC on profitability, with a higher operating margin.
BGLC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$422.7K | +$336.6K |
| Q1 2026 | -$148K | +$685.1K |
| Q4 2025 | $960.1K | +$1M |
| Q2 2025 | -$759.4K | -$88.8K |
| Q1 2025 | -$833.1K | -$798.7K |
| Q4 2024 | -$73.8K | +$39.7K |
| Q2 2024 | -$670.5K | -$634.1K |
| Q1 2024 | -$34.4K | +$84K |
BGLC has burned cash in most quarters: −$853,600 over the past year, against −$2M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BGLC on cash generation, producing positive trailing cash flow while its opponent burns cash.
BGLC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +35% | +621K shares |
| 3 years | +37% | +647K shares |
| 5 years | +69% | +990K shares |
| Available history | +294% | +1.8M shares |
BGLC has 2M diluted shares, up 35% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BGLC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BGLC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -3.9x | Net Cash |
| Q2 2022 | -0.9x | Net Cash |
| Q1 2022 | -2.2x | Net Cash |
| Q4 2021 | -1.9x | Net Cash |
| Q3 2021 | -0.7x | Net Cash |
| Q2 2021 | -0.8x | Net Cash |
| Q1 2021 | -1.4x | Net Cash |
| Q4 2020 | -2.0x | Net Cash |
BGLC has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BGLC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.0 | Oversold |
| Stochastic | 4.3 | Oversold |
BGLC's weekly RSI is 30 (oversold) and its Stochastic is 4 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BGLC PE vs Healthcare Sector
| Metric | BGLC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BGLC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BGLC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.12 | 19% below |
| 20 week MA | $1.42 | 36% below |
| 50 week MA | $2.19 | 58% below |
| 100 week MA | $3.15 | 71% below |
| 200 week MA | $12.5 | 93% below |
BGLC is in a downtrend: it's below all five of its weekly moving averages, and 93% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BGLC on trend strength, trading above more of its moving averages.
BGLC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $264.0 | $228.0 | -14% |
| 2022 | $228.0 | $114.0 | -50% |
| 2023 | $114.0 | $5.30 | -95% |
| 2024 | $5.30 | $2.67 | -50% |
| 2025 | $2.67 | $4.14 | +55% |
| 2026 YTD | $4.14 | $0.91 | -78% |
BGLC has finished lower in four of the last five years. It's down 78% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BGLC on returns for 2026, with the stronger performance.